Post-earnings recap
Reported
Thu, Oct 27, 2016
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
This earnings report indicates that United Therapeutics is performing well in terms of profitability, as shown by the significant EPS beat. The stock's positive reaction of 2.88% suggests that investors are encouraged by the company's financial health. However, the lack of revenue data and guidance leaves some uncertainty about future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $4.36 | N/A | +25.50% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the earnings performance, particularly the EPS beat. They emphasized their commitment to innovation and growth.
We are pleased with our EPS performance this quarter.
Our focus remains on delivering innovative therapies.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—